LCTX

Lineage Cell Therapeutics, Inc.

1.04

USD

-0.04

-3.70%

Nov 10, 15:22 UTC -5

Closed

After-Market

1.04

0.00

+0.10%

Lineage Cell Therapeutics, Inc. (LCTX) Earnings

LCTX Earnings Reports

Positive Surprise Ratio

LCTX beat 24 of 43 last estimates.

56%

Next Report

In 2 Days

Date of Next Report

Nov 12, 2026

Estimate for Q3 26 (Revenue/ EPS)

$2.03M

-$0.02

Implied change from Q2 26 (Revenue/ EPS)

+90.01%

-300.00%

Implied change from Q3 25 (Revenue/ EPS)

-44.82%

-84.62%

Lineage Cell Therapeutics, Inc. earnings per share and revenue

On Aug 06, 2026, LCTX reported earnings of 0.01 USD per share (EPS) for Q2 26, beating the estimate of -0.02 USD, resulting in a 134.60% surprise. Revenue reached 1.07 million, compared to an expected 1.56 million, with a -31.54% difference. The market reacted with a -2.65% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.02 USD, with revenue projected to reach 2.03 million USD, implying an decrease of -300.00% EPS, and increase of 90.01% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Lineage Cell Therapeutics, Inc.'s earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Lineage Cell Therapeutics, Inc. reported EPS of $0.01, beating estimates by 134.6%, and revenue of $1.07M, -31.54% below expectations.

How did the market react to Lineage Cell Therapeutics, Inc.'s Q2 2026 earnings?

The stock price moved down -2.65%, changed from $1.13 before the earnings release to $1.10 the day after.

When is Lineage Cell Therapeutics, Inc. expected to report next?

The next earning report is scheduled for Nov 12, 2026.

What are the forecasts for Lineage Cell Therapeutics, Inc.'s next earnings report?

Based on 7 analysts, Lineage Cell Therapeutics, Inc. is expected to report EPS of -$0.02 and revenue of $2.03M for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.